Abemaciclib AE Monitoring

	Assessment	At Baseline	Month-1				Month-2				Month-3	Month-4	Month-5 and Beyond
	CBC	X	Week-1	× Week-2	Week-3	× Week-4	Week-1	× Week-2	Week-3	× Week-4	Monthly	Monthly	As clinically indicated
	LFTsª	X	Week-1	× Week-2	Week-3	× Week-4	Week-1	× Week-2	Week-3	× Week-4	Monthly	Monthly	As clinically indicated
	Diarrhea	Instruct patients at the first sign of loose stools to initiate antidiarrheal therapy, increase oral fluids, and notify their healthcare provider.											
	ILD/ pneumonitis	Monitor for clinical symptoms or radiological changes indicative of ILD/pneumonitis. Perma- nently discontinue abemaciclib in all patients with grade 3 or 4 ILD or pneumonitis.											
	VTE	Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate.											
Ø	Embryo-fetal toxicity	Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.											



Please refer to the Full Prescribing Information for abemaciclib in the link below, scan the QR code, or obtain from a Lilly representative. https://pi.lilly.com/us/verzenio-uspi.pdf?s=p

Disclaimer Disclaimer This information is provided in response to your unsolicited request and is intended for your scientific and/or educational purpose and is not intended for promotional use and its use is at your discretion This information may contain substantive discussion of developmental compound(s) not approved for marketing and/or products approved for marketing but for uses, dosages, formulations, and/or populations different than those discussed in these materials For marketed products, please consult the product labeling for information on the specific uses, dosages, formulations and populations for which they are approved. Refer to www.lilly.com for labeling material if it has not been provided



^aALT, AST, and serum bilirubin.

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; ILD, interstitial lung disease; LFTs, liver function tests; VTE, venous thromboembolism.

Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.